Navigation Links
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Date:9/16/2009

PITTSBURGH, Sept. 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.

Mylan's product represents the first-ever fixed-dose combination of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate and now provides Matrix with numerous Tenofovir combination product opportunities. This new drug adds to the Matrix portfolio of important treatments for HIV/AIDS. The product may be used for either first- or second-line treatment in adults. People use second-line therapies if and when they develop resistance to initially prescribed treatments.

Mylan President Heather Bresch said: "This product represents yet another important advance in our continuing fight against the global epidemic of HIV/AIDS. By combining three antiretroviral (ARV) products into a once-daily dose, we can dramatically improve the quality of care for people living with HIV/AIDS in emerging markets. Lower pill burden also increases the likelihood that patients adhere to treatment. This innovation also adds another affordable option to our large and rapidly growing portfolio of life-sustaining ARV products."

The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. Although existing patents or exclusivity prevent its marketing in the U.S., the product will be eligible for purchase outside the U.S. in many developing countries.

Matrix's wide range of ARV products includes active pharmaceutical ingredients and first- and second-line finished doses. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries who are receiving treatment depend on Matrix ARV products.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
2. Matrixx Initiatives, Inc. Names William J. Hemelt President, CEO and Board Member
3. Matrixx Initiatives to Webcast 2009 Annual Stockholder Meeting Wednesday, August 26, 2009
4. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
5. Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
6. Matrixx Initiatives, Inc. Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results
7. MedInsights Partners With myMatrixx(TM) for Workers Compensation Pharmacy Benefit Management
8. Matrixx Initiatives Confirms Voluntary Recall of Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Gel Swabs
9. Matrixx Initiatives, Inc. Sets Time for Discussion of Recent FDA Action
10. Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel
11. Matrixx Initiatives, Inc. Received a Warning Letter From the Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Sugar Land, TX (PRWEB) , ... February 12, ... ... the families of southwest Houston and surrounding communities by continuing it’s commitment to ... Fort Bend Family Promise. The organization works closely with area homeless families to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic ... for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ... in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and ...
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... the field of long term care. With that, says Patrick Loughney, president of ... in administrative roles in long term care environments. His company, which offers prep ...
(Date:2/12/2016)... ... ... Planet Future is a Final Cut Pro X themed package ... pictures, videos as well as text in an exciting cartoon environment. Planet Future is ... beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media into the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
Breaking Medicine Technology: